Therapeutic Prospects of Cardiac Gene Transfer

Heart Lung and Circulation

Volumn 16, Issue 3, 2007, Pages 180-184

  Kizana, Eddy ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Arrhythmia; Gene therapy; Heart failure

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOVIRUS VECTOR; BETA 2 ADRENERGIC RECEPTOR; FOCAL INHIBITORY G PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; LENTIVIRUS VECTOR; NUCLEIC ACID; OLIGONUCLEOTIDE; PARVOVIRUS VECTOR; PHOSPHOLAMBAN; PROTEIN SERCA2A; UNCLASSIFIED DRUG;

ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DNA MODIFICATION; GENE THERAPY; GENE TRANSFER; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; MEDICAL TECHNOLOGY; MONOGENIC DISORDER; MORBIDITY; MORTALITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ARRHYTHMIA; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 34248574570     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2007.02.106     Document Type: Article

References (36)

1. Marban E. Gene therapy for common acquired diseases of the heart: the Sirens' song. Circulation 101 (2000) 1498-1499
2. Couzin J., and Kaiser J. Gene therapy. As Gelsinger case ends, gene therapy suffers another blow. Science 307 (2005) 1028
3. Kay M.A., Glorioso J.C., and Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7 (2001) 33-40
4. Nishikawa M., and Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 12 (2001) 861-870
5. Isner J.M., Vale P.R., Symes J.F., and Losordo D.W. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res 89 (2001) 389-400
6. Trono D. Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Ther 7 (2000) 20-23
7. Fleury S., Simeoni E., Zuppinger C., Deglon N., von Segesser L.K., Kappenberger L., and Vassalli G. Multiply attenuated, self-inactivating lentiviral vectors efficiently deliver and express genes for extended periods of time in adult rat cardiomyocytes in vivo. Circulation 107 (2003) 2375-2382
8. Monahan P.E., and Samulski R.J. AAV vectors: is clinical success on the horizon?. Gene Ther 7 (2000) 24-30
9. Xiao X., Li J., and Samulski R.J. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 70 (1996) 8098-8108
10. Hoshijima M., Ikeda Y., Iwanaga Y., Minamisawa S., Date M.O., Gu Y., Iwatate M., Li M., Wang L., Wilson J.M., Wang Y., Ross J., and Chien K.R. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8 (2002) 864-871
11. Wu Z., Asokan A., and Samulski R.J. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 14 (2006) 316-327
12. Gregorevic P., Blankinship M.J., Allen J.M., Crawford R.W., Meuse L., Miller D.G., Russell D.W., and Chamberlain J.S. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10 (2004) 828-834
13. Wang Z., Zhu T., Qiao C., Zhou L., Wang B., Zhang J., Chen C., Li J., and Xiao X. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 23 (2005) 321-328
14. Inagaki K., Fuess S., Storm T.A., Gibson G.A., Mctiernan C.F., Kay M.A., and Nakai H. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 14 (2006) 45-53
15. Pacak C.A., Mah C.S., Thattaliyath B.D., Conlon T.J., Lewis M.A., Cloutier D.E., Zolotukhin I., Tarantal A.F., and Byrne B.J. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 99 (2006) e3-e9
16. Hajjar R.J., del Monte F., Matsui T., and Rosenzweig A. Prospects for gene therapy for heart failure. Circ Res 86 (2000) 616-621
17. del Monte F., Harding S.E., Schmidt U., Matsui T., Kang Z.B., Dec G.W., Gwathmey J.K., Rosenzweig A., and Hajjar R.J. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 100 (1999) 2308-2311
18. Miyamoto M.I., del Monte F., Schmidt U., DiSalvo T.S., Kang Z.B., Matsui T., Guerrero J.L., Gwathmey J.K., Rosenzweig A., and Hajjar R.J. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A 97 (2000) 793-798
19. Del Monte F., Williams E., Lebeche D., Schmidt U., Rosenzweig A., Gwathmey J.K., Lewandowski E.D., and Hajjar R.J. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation 104 (2001) 1424-1429
20. Del Monte F., Lebeche D., Guerrero J.L., Tsuji T., Doye A.A., Gwathmey J.K., and Hajjar R.J. Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci U S A 101 (2004) 5622-5627
21. Muller O.J., Kaul F., Weitzman M.D., Pasqualini R., Arap W., Kleinschmidt J.A., and Trepel M. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 21 (2003) 1040-1046
22. Edelberg J.M., Aird W.C., and Rosenberg R.D. Enhancement of murine cardiac chronotropy by the molecular transfer of the human beta2 adrenergic receptor cDNA. J Clin Invest 101 (1998) 337-343
23. Miake J., Marban E., and Nuss H.B. Gene therapy: Biological pacemaker created by gene transfer. Nature 419 (2002) 132-133
24. Qu J., Plotnikov A.N., Danilo Jr. P., Shlapakova I., Cohen I.S., Robinson R.B., and Rosen M.R. Expression and function of a biological pacemaker in canine heart. Circulation 107 (2003) 1106-1109
25. Plotnikov A.N., Sosunov E.A., Qu J., Shlapakova I.N., Anyukhovsky E.P., Liu L., Janse M.J., Brink P.R., Cohen I.S., Robinson R.B., Danilo Jr. P., and Rosen M.R. Biological pacemaker implanted in canine left bundle branch provides ventricular escape rhythms that have physiologically acceptable rates. Circulation 109 (2004) 506-512
26. Tse H.F., Xue T., Lau C.P., Siu C.W., Wang K., Zhang Q.Y., Tomaselli G.F., Akar F.G., and Li R.A. Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN Channel reduces the dependence on electronic pacemaker in a sick-sinus syndrome model. Circulation 114 (2006) 1000-1011
27. Bucchi A., Plotnikov A.N., Shlapakova I., Danilo Jr. P., Kryukova Y., Qu J., Lu Z., Liu H., Pan Z., Potapova I., KenKnight B., Girouard S., Cohen I.S., Brink P.R., Robinson R.B., and Rosen M.R. Wild-type and mutant HCN channels in a tandem biological-electronic cardiac pacemaker. Circulation 114 (2006) 992-999
28. Kashiwakura Y., Cho H.C., Barth A.S., Azene E., and Marban E. Gene transfer of a synthetic pacemaker channel into the heart: a novel strategy for biological pacing. Circulation 114 (2006) 1682-1686
29. Donahue J.K., Heldman A.W., Fraser H., McDonald A.D., Miller J.M., Rade J.J., Eschenhagen T., and Marban E. Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med 6 (2000) 1395-1398
30. Kizana E., Ginn S.L., Allen D.G., Ross D.L., and Alexander I.E. Fibroblasts can be genetically modified to produce excitable cells capable of electrical coupling. Circulation 111 (2005) 394-398
31. Johns D.C., Nuss H.B., Chiamvimonvat N., Ramza B.M., Marban E., and Lawrence J.H. Adenovirus-mediated expression of a voltage-gated potassium channel in vitro (rat cardiac myocytes) and in vivo (rat liver). A novel strategy for modifying excitability. J Clin Invest 96 (1995) 1152-1158
32. Nuss H.B., Johns D.C., Kaab S., Tomaselli G.F., Kass D., Lawrence J.H., and Marban E. Reversal of potassium channel deficiency in cells from failing hearts by adenoviral gene transfer: a prototype for gene therapy for disorders of cardiac excitability and contractility. Gene Ther 3 (1996) 900-912
33. Ennis I.L., Li R.A., Murphy A.M., Marban E., and Nuss H.B. Dual gene therapy with SERCA1 and Kir2.1 abbreviates excitation without suppressing contractility. J Clin Invest 109 (2002) 393-400
34. Mazhari R., Nuss H.B., Armoundas A.A., Winslow R.L., and Marban E. Ectopic expression of KCNE3 accelerates cardiac repolarization and abbreviates the QT interval. J Clin Invest 109 (2002) 1083-1090
35. Brunner M., Kodirov S.A., Mitchell G.F., Buckett P.D., Shibata K., Folco E.J., Baker L., Salama G., Chan D.P., Zhou J., and Koren G. In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype. Am J Physiol Heart Circ Physiol 285 (2003) H194-H203
36. Sasano T., McDonald A.D., Kikuchi K., and Donahue J.K. Molecular ablation of ventricular tachycardia after myocardial infarction. Nat Med 12 (2006) 1256-1258